MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jconrel.2025.114061

Медицинская библиотека · Journal of controlled release : official journal of the Controlled Release Society · 2025

Low-dose inhalable amino acid-modified multilamellar nanoparticles activate STING for safe and effective regression of lung metastases.

Zhang Ruoshi, Wu Chengcheng, Yu Lvshan, Peng Cheng, Li Sai, Kuai Rui

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Lung metastases present a significant therapeutic challenge, as disseminated tumor cells evade surgical resection and often resist systemic treatments. Pulmonary delivery of immunostimulatory agents, such as the STING agonist cyclic GMP-AMP (cGAMP), offers a promising strategy to activate mucosal immunity and suppress metastatic progression. However, current pulmonary delivery systems are hindered by aerosolization-induced instability, mucus entrapment, and inefficient cytosolic drug release. To overcome these barriers, we developed an inhalable formulation consisting of a hyaluronic acid (HA)-lipid hybrid multilamellar nanoparticle encapsulating cGAMP (HLHC). The HA-lipid stacking architecture confers an 8.5-fold increase in mechanical rigidity compared to conventional liposomes, preserving structural integrity during nebulization and enhancing pulmonary retention. Moreover, the multilamellar structure and HA surface coating enable a 35-fold improvement in mucus penetration relative to standard liposomal controls. Importantly, systematic screening of amino acid-modified ionizable lipids identified arginine-modified variants (Arg-HLHC) as the most effective for cytosolic cGAMP delivery. Low-dose pulmonary administration of Arg-HLHC (1.5 μg cGAMP per dose) induced complete regression (100 %) of established lung metastases in the MC38-luc model, significantly outperforming state-of-the-art lipid nanoparticles (analogous to Onpattro®) delivering the same cGAMP dose. Notably, Arg-HLHC triggered robust local STING activation without eliciting systemic inflammation. This modular nanoplatform-combining hierarchical structural reinforcement with rational lipid design-addresses key translational challenges in pulmonary STING agonist delivery, establishing a safe, curative, and low-dose therapeutic strategy for lung metastases with broad potential for next-generation respiratory immunotherapies.

Для цитирования: Zhang Ruoshi, Wu Chengcheng, Yu Lvshan, Peng Cheng, Li Sai, Kuai Rui. Low-dose inhalable amino acid-modified multilamellar nanoparticles activate STING for safe and effective regression of lung metastases.. Journal of controlled release : official journal of the Controlled Release Society. 2025. DOI: 10.1016/j.jconrel.2025.114061.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.